Роль матриксных металлопротеиназ в развитии атеросклероза
Ключевые слова:
атеросклероз, ишемическая болезнь сердца, коронарный атеросклероз, инфаркт миокарда, ММП
Аннотация
Физиологическая роль матриксных металлопротеиназ (ММП) заключается в регуляции экстрацеллюлярного матрикса. При развитии ряда патологических процессов секреция ММП клетками мезенхимального ряда и иммунокомпетентными клетками значительно повышается, что вызывает соответствующее ремоделирование матрикса. Значение матриксных металлопротеиназ крайне широко и распространяется на многие отрасли здравоохранения. Известно, что ММП участвуют в процессе метастазирования опухолей, следовательно, изучение их активности может помочь в разработке новых методов диагностики и терапии злокачественных новообразований. Более того, ММП связаны с деградацией хряща при остеоартрите. Их ингибиторы могут быть использованы для замедления прогрессирования заболевания. В контексте сердечно-сосудистой патологии, ММП привлекают внимание в связи с их значимым участием в ремоделировании сосудистой стенки. Цель исследования – на основании анализа научной литературы уточнить роль матриксных металлопротеиназ в патогенезе коронарного атеросклероза. Проведен обзор литературы с элементами систематического обзора. Поиск статей производился через три онлайн-базы данных (Pubmed, Google Scholar и Cyberleninka). Критерии включения: полнотекстовые оригинальные статьи на английском и русском языках, исследования, в которых сообщалось о ММП при атеросклерозе и/или ИБС, и клинические исследования. Критериями исключения были: тезисы конференций, редакционные статьи, информационные бюллетени, книги и главы книг. Широкий спектр сердечно-сосудистых патологий, в том числе атеросклероз, во многом зависит от оборота экстрацеллюлярного матрикса. Дисбаланс между уровнем MMП и тканевыми ингибиторами металлопротеиназ приводит к нарушению регуляции протеолитической активности и неблагоприятному ремоделированию внеклеточного матрикса, который связан с прогрессированием и нестабильностью атеросклеротических бляшек в коронарных артериях. В результате повышенной активности матриксных металлопротеиназ, а также их дисбаланса с тканевыми ингибиторами металлопротеиназ происходит ремоделирование экстрацеллюлярного матрикса, из-за чего атеросклеротическая бляшка становится наиболее подверженной к разрыву. Поскольку чрезмерное ремоделирование тканей и повышенная активность ММП являются частью патогенеза атеросклеротического поражения, матриксные металлопротеиназы по-прежнему являются привлекательной мишенью для разработки антиатеросклеротических препаратов.
Скачивания
Данные скачивания пока недоступны.
Литература
1. Ежов М.В., Кухарчук В.В., Сергиенко И.В., Алиева А.С., Анциферов М.Б., Аншелес А.А., Арабидзе Г.Г., Аронов Д.М., Арутюнов Г.П., Ахмеджанов Н.М., Балахонова Т.В., Барбараш О.Л., Бойцов С.А., Бубнова М.Г., Воевода М.И., Галстян Г.Р., Галявич А.С., Горнякова Н.Б., Гуревич В.С., Дедов И.И., Драпкина О.М., Дупляков Д.В., Ерегин С.Я., Ершова А.И., Иртюга О.Б., Карпов С.Р., Карпов Ю.А., Качковский М.А., Кобалава Ж.Д., Козиолова Н.А., Коновалов Г.А., Константинов В.О., Космачева Е.Д., Котовская Ю.В., Мартынов А.И., Мешков А.Н., Небиеридзе Д.В., Недогода С.В., Обрезан А.Г., Олейников В.Э., Покровский С.Н., Рагино Ю.И., Ротарь О.П., Скибицкий В.В., Смоленская О.Г., Соколов А.А., Сумароков А.Б., Филиппов А.Е., Халимов Ю.Ш., Чазова И.Е., Шапошник И.И., Шестакова М.В., Якушин С.С., Шляхто Е.В. Нарушения липидного обмена. Клинические рекомендации 2023. Российский кардиологический журнал. 2023;28(5):5471. https://doi.org/10.15829/1560-4071-2023-5471 Ezhov M.V., Kukharchuk V.V., Sergienko i.V., Alieva A.S., Antsiferov M.B., Ansheles A.A., Arabidze G.G., Aronov D.M., Arutyunov G.P., Akhmedzhanov N.M., Balakhonova T.V., Barbarash O.L., Boytsov S.A., Bubnova M.G., Voevoda M.I., Galstyan G.R., Galyavich A.S., Gornyakova N.B., Gurevich V.S., Dedov I.I., Drapkina O.M., Duplyakov D.V., Eregin S.Ya., Ershova A.I., Irtyuga O.B., Karpov R.S., Karpov Yu.A., Kachkovsky M.A., Kobalava Zh.D., Koziolova N.A., Konovalov G.A., Konstantinov V.O., Kosmacheva E.D., Kotovskaya Yu.V., Martynov A.I., Meshkov A.N., Nebieridze D.V., Nedogoda S.V., Obrezan A.G., Oleinikov V.E., Pokrovsky S.N., Ragino Yu.I., Rotar O.P., Skibitsky V.V., Smolenskaya O.G., Sokolov A.A., Sumarokov A.B., Filippov E., Halimov Yu.Sh., Chazova I.E., Shaposhnik I.I., Shestakova M.V., Yakushin S.S., Shlyakhto E.V. Disorders of lipid metabolism. Clinical Guidelines 2023. Russian Journal of Cardiology. 2023;28(5):5471. (In Russ.) https://doi.org/10.15829/1560-4071-2023-5471
2. Chávez-Sánchez L, Espinosa-Luna JE, Chávez-Rueda K, Legorreta-Haquet MV, Montoya-Díaz E, Blanco-Favela F. Innate immune system cells in atherosclerosis. Arch Med Res. 2014 Jan;45(1):1-14. doi: 10.1016/j.arcmed.2013.11.007. Epub 2013 Dec 8. PMID: 24326322.
3. Libby P, Hansson GK. Inflammation and immunity in diseases of the arterial tree: players and layers. Circ Res. 2015 Jan 16;116(2):307-11. doi: 10.1161/CIRCRESAHA.116.301313. PMID: 25593275; PMCID: PMC4299915.
4. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med. 1999 Jan 14;340(2):115-26. doi: 10.1056/NEJM199901143400207. PMID: 9887164
5. Cabral-Pacheco GA, Garza-Veloz I, Castruita-De la Rosa C, et al. The Roles of Matrix Metalloproteinases and Their Inhibitors in Human Diseases. Int J Mol Sci. 2020;21(24):9739. Published 2020 Dec 20. doi:10.3390/ijms21249739
6. Matrix metalloproteinases, vascular remodeling, and vascular disease/ Wang X., Khalil R.A. // Adv. Pharm. – 2018. - C.241–330
7. Marino-Puertas L, Goulas T, Gomis-Rüth FX. Matrix metalloproteinases outside vertebrates. Biochim Biophys Acta Mol Cell Res. 2017 Nov;1864(11 Pt A):2026-2035. doi: 10.1016/j.bbamcr.2017.04.003. Epub 2017 Apr 7. PMID: 28392403
8. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res. 2002 Feb 22;90(3):251-62. PMID: 11861412.
9. Matrix metalloproteinases – From the cleavage data to the prediction tools and beyond/ Cieplak P., Strongin A.Y. // Biochim Biophys Acta. - 2017. - doi: 10.1016/j.bbamcr.2017.03.010.
10. Rienks M, Papageorgiou AP, Frangogiannis NG, Heymans S. Myocardial extracellular matrix: an ever-changing and diverse entity. Circ Res. 2014;114(5):872-888. doi:10.1161/CIRCRESAHA.114.302533
11. Spinale FG, Villarreal F. Targeting matrix metalloproteinases in heart disease: lessons from endogenous inhibitors. Biochem Pharmacol. 2014;90(1):7-15. doi:10.1016/j.bcp.2014.04.011
12. Morris DR, Biros E, Cronin O, Kuivaniemi H, Golledge J. The association of genetic variants of matrix metalloproteinases with abdominal aortic aneurysm: a systematic review and meta-analysis. Heart. 2014;100(4):295-302. doi:10.1136/heartjnl-2013-304129
13. Vacek TP, Rehman S, Neamtu D, Yu S, Givimani S, Tyagi SC. Matrix metalloproteinases in atherosclerosis: role of nitric oxide, hydrogen sulfide, homocysteine, and polymorphisms. Vasc Health Risk Manag. 2015;11:173-183. Published 2015 Feb 27. doi:10.2147/VHRM.S68415
14. Bentzon JF, Otsuka F, Virmani R, Falk E. Mechanisms of plaque formation and rupture. Circ Res. 2014;114(12):1852-1866. doi:10.1161/CIRCRESAHA.114.302721
15. Johnson J. L. Matrix metalloproteinases: influence on smooth muscle cells and atherosclerotic plaque stability. Expert Review of Cardiovascular Therapy . 2007;5(2):265–282. doi: 10.1586/14779072.5.2.265.
16. Shah P. K. Biomarkers of plaque instability. Current Cardiology Reports . 2014;16 doi: 10.1007/s11886-014-0547-7.547
17. Johnson JL, Jenkins NP, Huang WC, et al. Relationship of MMP-14 and TIMP-3 expression with macrophage activation and human atherosclerotic plaque vulnerability. Mediators Inflamm. 2014;2014:276457. doi:10.1155/2014/276457
18. Kremastiotis G, Handa I, Jackson C, George S, Johnson J. Disparate effects of MMP and TIMP modulation on coronary atherosclerosis and associated myocardial fibrosis. Sci Rep. 2021;11(1):23081. Published 2021 Nov 30. doi:10.1038/s41598-021-02508-4
19. Sakakura K., Nakano M., Otsuka F., Ladich E., Kolodgie F. D., Virmani R. Pathophysiology of atherosclerosis plaque progression. Heart, Lung and Circulation. 2013;22(6):399–411. doi: 10.1016/j.hlc.2013.03.001.
20. Falk E., Nakano M., Bentzon J. F., Finn A. V., Virmani R. Update on acute coronary syndromes: the pathologists’ view. European Heart Journal. 2013;34(10):719–728. doi: 10.1093/eurheartj/ehs411
21. Loftus I. Mechanisms of plaque rupture. In: Fitridge R., Thompson M., editors. Mechanisms of Vascular Disease: A Reference Book for Vascular Specialists . University of Adelaide Press; 2011. p. p. 4
22. Lee S. J., Seo K. W., Yun M. R., et al. 4-Hydroxynonenal enhances MMP-2 production in vascular smooth muscle cells via mitochondrial ROS-mediated activation of the Akt/NF-κB signaling pathways. Free Radical Biology and Medicine . 2008;45(10):1487–1492. doi: 10.1016/j.freeradbiomed.2008.08.022
23. Leonarduzzi G., Chiarpotto E., Biasi F., Poli G. 4-Hydroxynonenal and cholesterol oxidation products in atherosclerosis. Molecular Nutrition & Food Research . 2005;49(11):1044–1049. doi: 10.1002/mnfr.200500090
24. Newby A. C., Zaltsman A. B. Fibrous cap formation or destruction—the critical importance of vascular smooth muscle cell proliferation, migration and matrix formation. Cardiovascular Research . 1999;41(2):345–360. doi: 10.1016/S0008-6363(98)00286-7.
25. Samah N, Ugusman A, Hamid AA, Sulaiman N, Aminuddin A. Role of Matrix Metalloproteinase-2 in the Development of Atherosclerosis among Patients with Coronary Artery Disease. Mediators Inflamm. 2023 Jul 7;2023:9715114. doi: 10.1155/2023/9715114. PMID: 37457745; PMCID: PMC10348858.
26. Massberg S, Brand K, Grüner S, Page S, Müller E, Müller I, Bergmeier W, Richter T, Lorenz M, Konrad I, Nieswandt B, Gawaz M. A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation. J Exp Med. 2002 Oct 7;196(7):887-96. doi: 10.1084/jem.20012044. PMID: 12370251; PMCID: PMC2194025
27. Simões G, Pereira T, Caseiro A. Matrix metaloproteinases in vascular pathology. Microvasc Res. 2022;143:104398. doi:10.1016/j.mvr.2022.104398
28. King SM, McNamee RA, Houng AK, Patel R, Brands M, Reed GL. Platelet dense-granule secretion plays a critical role in thrombosis and subsequent vascular remodeling in atherosclerotic mice. Circulation. 2009 Sep 1;120(9):785-91. doi: 10.1161/CIRCULATIONAHA.108.845461. Epub 2009 Aug 17. PMID: 19687360; PMCID: PMC2761818.
29. Gresele P, Falcinelli E, Sebastiano M, Momi S. Matrix Metalloproteinases and Platelet Function. Prog Mol Biol Transl Sci. 2017;147:133-165. doi: 10.1016/bs.pmbts.2017.01.002. Epub 2017 Mar 21. PMID: 28413027.
30. Busti C, Falcinelli E, Momi S, Gresele P. Matrix metalloproteinases and peripheral arterial disease. Intern Emerg Med. 2010 Feb;5(1):13-25. doi: 10.1007/s11739-009-0283-y. Epub 2009 Jul 21. Erratum in: Intern Emerg Med. 2010 Feb;5(1):89. PMID: 19626421.
31. Frenette PS, Moyna C, Hartwell DW, Lowe JB, Hynes RO, Wagner DD. Platelet-endothelial interactions in inflamed mesenteric venules. Blood. 1998 Feb 15;91(4):1318-24. PMID: 9454762.
32. Sluijter JP, Pulskens WP, Schoneveld AH, Velema E, Strijder CF, Moll F, de Vries JP, Verheijen J, Hanemaaijer R, de Kleijn DP, Pasterkamp G. Matrix metalloproteinase 2 is associated with stable and matrix metalloproteinases 8 and 9 with vulnerable carotid atherosclerotic lesions: a study in human endarterectomy specimen pointing to a role for different extracellular matrix metalloproteinase inducer glycosylation forms. Stroke. 2006 Jan;37(1):235-9. doi: 10.1161/01.STR.0000196986.50059.e0. Epub 2005 Dec 8. PMID: 16339461
33. Kuzuya M, Nakamura K, Sasaki T, Cheng XW, Itohara S, Iguchi A. Effect of MMP-2 deficiency on atherosclerotic lesion formation in apoE-deficient mice. Arterioscler Thromb Vasc Biol. 2006 May;26(5):1120-5. doi: 10.1161/01.ATV.0000218496.60097.e0. Epub 2006 Mar 23. PMID: 16556856.
34. Sai L., YanQiu Z., DongMei C., YinJun L. Effect of rosuvastatin and benazepril on matrix metalloproteinase-2, matrix metalloproteinase-9 and leukotriene B4 of patients with acute myocardial infarction. Tropical Journal of Pharmaceutical Research . 2019;18(3):625–630. doi: 10.4314/tjpr.v18i3.26.
35. Li Y., Li L., Wang K., Wu P., Cui Y. Investigation on risk stratification and the prognostic value of hs-TnT combined with MMP-2 in patients with acute coronary syndrome. BioMed Research International . 2021;2021:5. doi: 10.1155/2021/1040171.1040171
36. Murashov I. S., Volkov A. M., Kazanskaya G. M., et al. Immunohistochemical features of different types of unstable atherosclerotic plaques of coronary arteries. Bulletin of Experimental Biology and Medicine . 2018;166:102–106. doi: 10.1007/s10517-018-4297-1.
37. Owolabi U. S., Amraotkar A. R., Coulter A. R., et al. Change in matrix metalloproteinase 2, 3, and 9 levels at the time of and after acute atherothrombotic myocardial infarction. Journal of Thrombosis and Thrombolysis . 2020;49:235–244. doi: 10.1007/s11239-019-02004-7.
38. Abbas A, Aukrust P, Russell D, et al. Matrix metalloproteinase 7 is associated with symptomatic lesions and adverse events in patients with carotid atherosclerosis. PLoS One. 2014;9(1):e84935. Published 2014 Jan 6. doi:10.1371/journal.pone.0084935
39. Lenglet S, Mach F, Montecucco F. Role of matrix metalloproteinase-8 in atherosclerosis. Mediators Inflamm. 2013;2013:659282. doi:10.1155/2013/659282
40. Vandooren J., Van den Steen P.E., Opdenakker G. Biochemistry and Molecular Biology of Gelatinase B or Matrix Metalloproteinase-9 (MMP-9): The next Decade. Crit. Rev. Biochem. Mol. Biol. 2013;48:222–272. doi: 10.3109/10409238.2013.770819.
41. Florence JM, Krupa A, Booshehri LM, Allen TC, Kurdowska AK. Metalloproteinase-9 contributes to endothelial dysfunction in atherosclerosis via protease activated receptor-1. PLoS One. 2017;12(2):e0171427. Published 2017 Feb 6. doi:10.1371/journal.pone.0171427
42. Guizani I, Zidi W, Zayani Y, et al. Matrix metalloproteinase 3 and 9 as genetic biomarkers for the occurrence of cardiovascular complications in coronary artery disease: a prospective cohort study. Mol Biol Rep. 2022;49(10):9171-9179. doi:10.1007/s11033-022-07742-1
43. Nagase H., Woessner J.F. Matrix Metalloproteinases. J. Biol. Chem. 1999;274:21491–21494. doi: 10.1074/jbc.274.31.21491
44. Mangge H, Almer G. Immune-Mediated Inflammation in Vulnerable Atherosclerotic Plaques. Molecules. 2019;24(17):3072. Published 2019 Aug 23. doi:10.3390/molecules24173072
45. Vandooren J, Born B, Solomonov I, et al. Circular trimers of gelatinase B/matrix metalloproteinase-9 constitute a distinct population of functional enzyme molecules differentially regulated by tissue inhibitor of metalloproteinases-1. Biochem J. 2015;465(2):259-270. doi:10.1042/BJ20140418
46. Li L, Li J, Yi J, Liu H, Lei H. Dose-Effect of Irbesartan on Cyclooxygenase-2 and Matrix Metalloproteinase-9 Expression in Rabbit Atherosclerosis. J Cardiovasc Pharmacol. 2018;71(2):82-94. doi:10.1097/FJC.0000000000000544
47. Chen Y, Waqar AB, Nishijima K, et al. Macrophage-derived MMP-9 enhances the progression of atherosclerotic lesions and vascular calcification in transgenic rabbits. J Cell Mol Med. 2020;24(7):4261-4274. doi:10.1111/jcmm.15087
48. Jin ZX, Xiong Q, Jia F, Sun CL, Zhu HT, Ke FS. Investigation of RNA interference suppression of matrix metalloproteinase-9 in mouse model of atherosclerosis. Int J Clin Exp Med. 2015;8(4):5272-5278. Published 2015 Apr 15
49. Gu C, Wang F, Hou Z, et al. Sex-related differences in serum matrix metalloproteinase-9 screening non-calcified and mixed coronary atherosclerotic plaques in outpatients with chest pain. Heart Vessels. 2017;32(12):1424-1431. doi:10.1007/s00380-017-1014-3
50. Silvello D, Narvaes LB, Albuquerque LC, et al. Serum levels and polymorphisms of matrix metalloproteinases (MMPs) in carotid artery atherosclerosis: higher MMP-9 levels are associated with plaque vulnerability. Biomarkers. 2014;19(1):49-55. doi:10.3109/1354750X.2013.866165
51. Heo SH, Cho CH, Kim HO, Jo YH, Yoon KS, Lee JH, Park JC, Park KC, Ahn TB, Chung KC, Yoon SS, Chang DI. Plaque rupture is a determinant of vascular events in carotid artery atherosclerotic disease: involvement of matrix metalloproteinases 2 and 9. J Clin Neurol. 2011;7:69–76. doi: 10.3988/jcn.2011.7.2.69.
52. Loftus IM, Naylor AR, Goodall S, Crowther M, Jones L, Bell PR, Thompson MM. Increased matrix metalloproteinase-9 activity in unstable carotid plaques. A potential role in acute plaque disruption. Stroke. 2000;31:40–47. doi: 10.1161/01.str.31.1.40.
53. Bräuninger H, Krüger S, Bacmeister L, Nyström A, Eyerich K, Westermann D, Lindner D. Matrix metalloproteinases in coronary artery disease and myocardial infarction. Basic Res Cardiol. 2023 May 9;118(1):18. doi: 10.1007/s00395-023-00987-2. PMID: 37160529; PMCID: PMC10169894
54. Ruddy JM, Ikonomidis JS, Jones JA. Multidimensional Contribution of Matrix Metalloproteinases to Atherosclerotic Plaque Vulnerability: Multiple Mechanisms of Inhibition to Promote Stability. J Vasc Res. 2016;53(1-2):1-16. doi:10.1159/000446703
55. Levin M, Udi Y, Solomonov I, Sagi I. Next generation matrix metalloproteinase inhibitors - Novel strategies bring new prospects. Biochim Biophys Acta Mol Cell Res. 2017;1864(11 Pt A):1927-1939. doi:10.1016/j.bbamcr.2017.06.009
56. Amar S, Minond D, Fields GB. Clinical Implications of Compounds Designed to Inhibit ECM-Modifying Metalloproteinases. Proteomics. 2017;17(23-24):10.1002/pmic.201600389. doi:10.1002/pmic.201600389
57. Fields GB. Mechanisms of Action of Novel Drugs Targeting Angiogenesis-Promoting Matrix Metalloproteinases. Front Immunol. 2019;10:1278. Published 2019 Jun 4. doi:10.3389/fimmu.2019.01278
2. Chávez-Sánchez L, Espinosa-Luna JE, Chávez-Rueda K, Legorreta-Haquet MV, Montoya-Díaz E, Blanco-Favela F. Innate immune system cells in atherosclerosis. Arch Med Res. 2014 Jan;45(1):1-14. doi: 10.1016/j.arcmed.2013.11.007. Epub 2013 Dec 8. PMID: 24326322.
3. Libby P, Hansson GK. Inflammation and immunity in diseases of the arterial tree: players and layers. Circ Res. 2015 Jan 16;116(2):307-11. doi: 10.1161/CIRCRESAHA.116.301313. PMID: 25593275; PMCID: PMC4299915.
4. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med. 1999 Jan 14;340(2):115-26. doi: 10.1056/NEJM199901143400207. PMID: 9887164
5. Cabral-Pacheco GA, Garza-Veloz I, Castruita-De la Rosa C, et al. The Roles of Matrix Metalloproteinases and Their Inhibitors in Human Diseases. Int J Mol Sci. 2020;21(24):9739. Published 2020 Dec 20. doi:10.3390/ijms21249739
6. Matrix metalloproteinases, vascular remodeling, and vascular disease/ Wang X., Khalil R.A. // Adv. Pharm. – 2018. - C.241–330
7. Marino-Puertas L, Goulas T, Gomis-Rüth FX. Matrix metalloproteinases outside vertebrates. Biochim Biophys Acta Mol Cell Res. 2017 Nov;1864(11 Pt A):2026-2035. doi: 10.1016/j.bbamcr.2017.04.003. Epub 2017 Apr 7. PMID: 28392403
8. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res. 2002 Feb 22;90(3):251-62. PMID: 11861412.
9. Matrix metalloproteinases – From the cleavage data to the prediction tools and beyond/ Cieplak P., Strongin A.Y. // Biochim Biophys Acta. - 2017. - doi: 10.1016/j.bbamcr.2017.03.010.
10. Rienks M, Papageorgiou AP, Frangogiannis NG, Heymans S. Myocardial extracellular matrix: an ever-changing and diverse entity. Circ Res. 2014;114(5):872-888. doi:10.1161/CIRCRESAHA.114.302533
11. Spinale FG, Villarreal F. Targeting matrix metalloproteinases in heart disease: lessons from endogenous inhibitors. Biochem Pharmacol. 2014;90(1):7-15. doi:10.1016/j.bcp.2014.04.011
12. Morris DR, Biros E, Cronin O, Kuivaniemi H, Golledge J. The association of genetic variants of matrix metalloproteinases with abdominal aortic aneurysm: a systematic review and meta-analysis. Heart. 2014;100(4):295-302. doi:10.1136/heartjnl-2013-304129
13. Vacek TP, Rehman S, Neamtu D, Yu S, Givimani S, Tyagi SC. Matrix metalloproteinases in atherosclerosis: role of nitric oxide, hydrogen sulfide, homocysteine, and polymorphisms. Vasc Health Risk Manag. 2015;11:173-183. Published 2015 Feb 27. doi:10.2147/VHRM.S68415
14. Bentzon JF, Otsuka F, Virmani R, Falk E. Mechanisms of plaque formation and rupture. Circ Res. 2014;114(12):1852-1866. doi:10.1161/CIRCRESAHA.114.302721
15. Johnson J. L. Matrix metalloproteinases: influence on smooth muscle cells and atherosclerotic plaque stability. Expert Review of Cardiovascular Therapy . 2007;5(2):265–282. doi: 10.1586/14779072.5.2.265.
16. Shah P. K. Biomarkers of plaque instability. Current Cardiology Reports . 2014;16 doi: 10.1007/s11886-014-0547-7.547
17. Johnson JL, Jenkins NP, Huang WC, et al. Relationship of MMP-14 and TIMP-3 expression with macrophage activation and human atherosclerotic plaque vulnerability. Mediators Inflamm. 2014;2014:276457. doi:10.1155/2014/276457
18. Kremastiotis G, Handa I, Jackson C, George S, Johnson J. Disparate effects of MMP and TIMP modulation on coronary atherosclerosis and associated myocardial fibrosis. Sci Rep. 2021;11(1):23081. Published 2021 Nov 30. doi:10.1038/s41598-021-02508-4
19. Sakakura K., Nakano M., Otsuka F., Ladich E., Kolodgie F. D., Virmani R. Pathophysiology of atherosclerosis plaque progression. Heart, Lung and Circulation. 2013;22(6):399–411. doi: 10.1016/j.hlc.2013.03.001.
20. Falk E., Nakano M., Bentzon J. F., Finn A. V., Virmani R. Update on acute coronary syndromes: the pathologists’ view. European Heart Journal. 2013;34(10):719–728. doi: 10.1093/eurheartj/ehs411
21. Loftus I. Mechanisms of plaque rupture. In: Fitridge R., Thompson M., editors. Mechanisms of Vascular Disease: A Reference Book for Vascular Specialists . University of Adelaide Press; 2011. p. p. 4
22. Lee S. J., Seo K. W., Yun M. R., et al. 4-Hydroxynonenal enhances MMP-2 production in vascular smooth muscle cells via mitochondrial ROS-mediated activation of the Akt/NF-κB signaling pathways. Free Radical Biology and Medicine . 2008;45(10):1487–1492. doi: 10.1016/j.freeradbiomed.2008.08.022
23. Leonarduzzi G., Chiarpotto E., Biasi F., Poli G. 4-Hydroxynonenal and cholesterol oxidation products in atherosclerosis. Molecular Nutrition & Food Research . 2005;49(11):1044–1049. doi: 10.1002/mnfr.200500090
24. Newby A. C., Zaltsman A. B. Fibrous cap formation or destruction—the critical importance of vascular smooth muscle cell proliferation, migration and matrix formation. Cardiovascular Research . 1999;41(2):345–360. doi: 10.1016/S0008-6363(98)00286-7.
25. Samah N, Ugusman A, Hamid AA, Sulaiman N, Aminuddin A. Role of Matrix Metalloproteinase-2 in the Development of Atherosclerosis among Patients with Coronary Artery Disease. Mediators Inflamm. 2023 Jul 7;2023:9715114. doi: 10.1155/2023/9715114. PMID: 37457745; PMCID: PMC10348858.
26. Massberg S, Brand K, Grüner S, Page S, Müller E, Müller I, Bergmeier W, Richter T, Lorenz M, Konrad I, Nieswandt B, Gawaz M. A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation. J Exp Med. 2002 Oct 7;196(7):887-96. doi: 10.1084/jem.20012044. PMID: 12370251; PMCID: PMC2194025
27. Simões G, Pereira T, Caseiro A. Matrix metaloproteinases in vascular pathology. Microvasc Res. 2022;143:104398. doi:10.1016/j.mvr.2022.104398
28. King SM, McNamee RA, Houng AK, Patel R, Brands M, Reed GL. Platelet dense-granule secretion plays a critical role in thrombosis and subsequent vascular remodeling in atherosclerotic mice. Circulation. 2009 Sep 1;120(9):785-91. doi: 10.1161/CIRCULATIONAHA.108.845461. Epub 2009 Aug 17. PMID: 19687360; PMCID: PMC2761818.
29. Gresele P, Falcinelli E, Sebastiano M, Momi S. Matrix Metalloproteinases and Platelet Function. Prog Mol Biol Transl Sci. 2017;147:133-165. doi: 10.1016/bs.pmbts.2017.01.002. Epub 2017 Mar 21. PMID: 28413027.
30. Busti C, Falcinelli E, Momi S, Gresele P. Matrix metalloproteinases and peripheral arterial disease. Intern Emerg Med. 2010 Feb;5(1):13-25. doi: 10.1007/s11739-009-0283-y. Epub 2009 Jul 21. Erratum in: Intern Emerg Med. 2010 Feb;5(1):89. PMID: 19626421.
31. Frenette PS, Moyna C, Hartwell DW, Lowe JB, Hynes RO, Wagner DD. Platelet-endothelial interactions in inflamed mesenteric venules. Blood. 1998 Feb 15;91(4):1318-24. PMID: 9454762.
32. Sluijter JP, Pulskens WP, Schoneveld AH, Velema E, Strijder CF, Moll F, de Vries JP, Verheijen J, Hanemaaijer R, de Kleijn DP, Pasterkamp G. Matrix metalloproteinase 2 is associated with stable and matrix metalloproteinases 8 and 9 with vulnerable carotid atherosclerotic lesions: a study in human endarterectomy specimen pointing to a role for different extracellular matrix metalloproteinase inducer glycosylation forms. Stroke. 2006 Jan;37(1):235-9. doi: 10.1161/01.STR.0000196986.50059.e0. Epub 2005 Dec 8. PMID: 16339461
33. Kuzuya M, Nakamura K, Sasaki T, Cheng XW, Itohara S, Iguchi A. Effect of MMP-2 deficiency on atherosclerotic lesion formation in apoE-deficient mice. Arterioscler Thromb Vasc Biol. 2006 May;26(5):1120-5. doi: 10.1161/01.ATV.0000218496.60097.e0. Epub 2006 Mar 23. PMID: 16556856.
34. Sai L., YanQiu Z., DongMei C., YinJun L. Effect of rosuvastatin and benazepril on matrix metalloproteinase-2, matrix metalloproteinase-9 and leukotriene B4 of patients with acute myocardial infarction. Tropical Journal of Pharmaceutical Research . 2019;18(3):625–630. doi: 10.4314/tjpr.v18i3.26.
35. Li Y., Li L., Wang K., Wu P., Cui Y. Investigation on risk stratification and the prognostic value of hs-TnT combined with MMP-2 in patients with acute coronary syndrome. BioMed Research International . 2021;2021:5. doi: 10.1155/2021/1040171.1040171
36. Murashov I. S., Volkov A. M., Kazanskaya G. M., et al. Immunohistochemical features of different types of unstable atherosclerotic plaques of coronary arteries. Bulletin of Experimental Biology and Medicine . 2018;166:102–106. doi: 10.1007/s10517-018-4297-1.
37. Owolabi U. S., Amraotkar A. R., Coulter A. R., et al. Change in matrix metalloproteinase 2, 3, and 9 levels at the time of and after acute atherothrombotic myocardial infarction. Journal of Thrombosis and Thrombolysis . 2020;49:235–244. doi: 10.1007/s11239-019-02004-7.
38. Abbas A, Aukrust P, Russell D, et al. Matrix metalloproteinase 7 is associated with symptomatic lesions and adverse events in patients with carotid atherosclerosis. PLoS One. 2014;9(1):e84935. Published 2014 Jan 6. doi:10.1371/journal.pone.0084935
39. Lenglet S, Mach F, Montecucco F. Role of matrix metalloproteinase-8 in atherosclerosis. Mediators Inflamm. 2013;2013:659282. doi:10.1155/2013/659282
40. Vandooren J., Van den Steen P.E., Opdenakker G. Biochemistry and Molecular Biology of Gelatinase B or Matrix Metalloproteinase-9 (MMP-9): The next Decade. Crit. Rev. Biochem. Mol. Biol. 2013;48:222–272. doi: 10.3109/10409238.2013.770819.
41. Florence JM, Krupa A, Booshehri LM, Allen TC, Kurdowska AK. Metalloproteinase-9 contributes to endothelial dysfunction in atherosclerosis via protease activated receptor-1. PLoS One. 2017;12(2):e0171427. Published 2017 Feb 6. doi:10.1371/journal.pone.0171427
42. Guizani I, Zidi W, Zayani Y, et al. Matrix metalloproteinase 3 and 9 as genetic biomarkers for the occurrence of cardiovascular complications in coronary artery disease: a prospective cohort study. Mol Biol Rep. 2022;49(10):9171-9179. doi:10.1007/s11033-022-07742-1
43. Nagase H., Woessner J.F. Matrix Metalloproteinases. J. Biol. Chem. 1999;274:21491–21494. doi: 10.1074/jbc.274.31.21491
44. Mangge H, Almer G. Immune-Mediated Inflammation in Vulnerable Atherosclerotic Plaques. Molecules. 2019;24(17):3072. Published 2019 Aug 23. doi:10.3390/molecules24173072
45. Vandooren J, Born B, Solomonov I, et al. Circular trimers of gelatinase B/matrix metalloproteinase-9 constitute a distinct population of functional enzyme molecules differentially regulated by tissue inhibitor of metalloproteinases-1. Biochem J. 2015;465(2):259-270. doi:10.1042/BJ20140418
46. Li L, Li J, Yi J, Liu H, Lei H. Dose-Effect of Irbesartan on Cyclooxygenase-2 and Matrix Metalloproteinase-9 Expression in Rabbit Atherosclerosis. J Cardiovasc Pharmacol. 2018;71(2):82-94. doi:10.1097/FJC.0000000000000544
47. Chen Y, Waqar AB, Nishijima K, et al. Macrophage-derived MMP-9 enhances the progression of atherosclerotic lesions and vascular calcification in transgenic rabbits. J Cell Mol Med. 2020;24(7):4261-4274. doi:10.1111/jcmm.15087
48. Jin ZX, Xiong Q, Jia F, Sun CL, Zhu HT, Ke FS. Investigation of RNA interference suppression of matrix metalloproteinase-9 in mouse model of atherosclerosis. Int J Clin Exp Med. 2015;8(4):5272-5278. Published 2015 Apr 15
49. Gu C, Wang F, Hou Z, et al. Sex-related differences in serum matrix metalloproteinase-9 screening non-calcified and mixed coronary atherosclerotic plaques in outpatients with chest pain. Heart Vessels. 2017;32(12):1424-1431. doi:10.1007/s00380-017-1014-3
50. Silvello D, Narvaes LB, Albuquerque LC, et al. Serum levels and polymorphisms of matrix metalloproteinases (MMPs) in carotid artery atherosclerosis: higher MMP-9 levels are associated with plaque vulnerability. Biomarkers. 2014;19(1):49-55. doi:10.3109/1354750X.2013.866165
51. Heo SH, Cho CH, Kim HO, Jo YH, Yoon KS, Lee JH, Park JC, Park KC, Ahn TB, Chung KC, Yoon SS, Chang DI. Plaque rupture is a determinant of vascular events in carotid artery atherosclerotic disease: involvement of matrix metalloproteinases 2 and 9. J Clin Neurol. 2011;7:69–76. doi: 10.3988/jcn.2011.7.2.69.
52. Loftus IM, Naylor AR, Goodall S, Crowther M, Jones L, Bell PR, Thompson MM. Increased matrix metalloproteinase-9 activity in unstable carotid plaques. A potential role in acute plaque disruption. Stroke. 2000;31:40–47. doi: 10.1161/01.str.31.1.40.
53. Bräuninger H, Krüger S, Bacmeister L, Nyström A, Eyerich K, Westermann D, Lindner D. Matrix metalloproteinases in coronary artery disease and myocardial infarction. Basic Res Cardiol. 2023 May 9;118(1):18. doi: 10.1007/s00395-023-00987-2. PMID: 37160529; PMCID: PMC10169894
54. Ruddy JM, Ikonomidis JS, Jones JA. Multidimensional Contribution of Matrix Metalloproteinases to Atherosclerotic Plaque Vulnerability: Multiple Mechanisms of Inhibition to Promote Stability. J Vasc Res. 2016;53(1-2):1-16. doi:10.1159/000446703
55. Levin M, Udi Y, Solomonov I, Sagi I. Next generation matrix metalloproteinase inhibitors - Novel strategies bring new prospects. Biochim Biophys Acta Mol Cell Res. 2017;1864(11 Pt A):1927-1939. doi:10.1016/j.bbamcr.2017.06.009
56. Amar S, Minond D, Fields GB. Clinical Implications of Compounds Designed to Inhibit ECM-Modifying Metalloproteinases. Proteomics. 2017;17(23-24):10.1002/pmic.201600389. doi:10.1002/pmic.201600389
57. Fields GB. Mechanisms of Action of Novel Drugs Targeting Angiogenesis-Promoting Matrix Metalloproteinases. Front Immunol. 2019;10:1278. Published 2019 Jun 4. doi:10.3389/fimmu.2019.01278
Опубликован
2025-06-23
Как цитировать
Изможерова Н. В., Попов А. А., Шамбатов М. А. о., Кожевникова А. К., Мелькова А. В. Роль матриксных металлопротеиназ в развитии атеросклероза // Патологическая физиология и экспериментальная терапия. 2025. Т. 69. № 2. С. 117–126.
Выпуск
Раздел
Обзоры
